RxDoctor Payments Data

Sangita Desai, MD

Psychiatry · Clearwater, FLNPI 1386795532

Payments from drug & device makers

$2,665in general payments, 2019–2025

Across 115 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$634
  • AbbVie$592
  • Teva Pharmaceuticals USA, Inc.$529
  • Otsuka America Pharmaceutical, Inc.$308
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
  • Johnson & Johnson$114
  • plus $229 from 4 others

What the payments were for

  • Food & beverage$2,55496%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,665 in reported general payments places this provider in the 70th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$13,668
Medicare patients
38
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate21$177,654
AustedoDeutetrabenazine14$70,439
Austedo XrDeutetrabenazine12$65,469
Clozapine206$20,847
Aripiprazole169$19,630
VraylarCariprazine Hcl11$15,056
Clomipramine Hcl12$11,620
Risperdal ConstaRisperidone Microspheres13$8,289
Effexor XrVenlafaxine Hcl12$6,590
Ziprasidone Hcl26$6,571
Lurasidone Hcl31$5,874
Divalproex Sodium ErDivalproex Sodium114$5,725
Quetiapine Fumarate208$4,663
Paliperidone ErPaliperidone26$3,664
Chlorpromazine Hcl22$3,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Risperdal Consta$114$185,94334 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$529$135,90826 claims
AbbVieVraylar$592$15,05611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →